Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cerevel Therapeutics Hldg Inc (NQ: CERE )

44.96 UNCHANGED
Last Price Updated: 4:15 PM EDT, Jul 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 44.96
Bid (Size) 44.97 (20)
Ask (Size) 44.98 (146)
Prev. Close 44.96
Today's Range 44.96 - 44.96
52wk Range 23.36 - 44.96
Shares Outstanding 8,830,700
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CERE Investors Have the Opportunity to Join Investigation of Cerevel Therapeutics Holdings, Inc. with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
CEREVEL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) Buyout and Encourages Investors to Contact the Firm
From Kaskela Law LLC
Via Business Wire

Performance

YTD
+6.52%
+6.52%
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
+5.74%
+5.74%
1 Year
+70.56%
+70.56%

More News

Read More
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165?
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
CERE Stock Earnings: Cerevel Therapeutics Hldg Misses EPS for Q2 2024
Via InvestorPlace
Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study
Via Benzinga
Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug
Via Investor's Business Daily
Tuesday Talk: Big-Tech Under Attack
Via Talk Markets
Why Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday?
Via Benzinga
3 Unstoppable Mega-Cap Stocks That Every Investor Should Own in 2024
Via InvestorPlace
Is AbbVie Stock a Buy Now?
Via The Motley Fool
This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space
Via Benzinga
UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst
Via Benzinga
AbbVie Lifts Long-Term Outlook For New Immunology Drugs, Even As Q4 Revenue and Profit Fall
Via Benzinga
AbbVie's Transformational 2023, Analyst Anticipates Growth in 2024 Amid Competitive Pressures
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: McGrath RentCorp (Nasdaq – MGRC), Science 37 Holdings, Inc. (Nasdaq – SNCE), Eagle Bulk Shipping Inc. (NYSE - EGLE), Cerevel Therapeutics Holdings, Inc. (Nasdaq –
From Brodsky & Smith LLC
Via GlobeNewswire
ABBV: This Top Biotech Just Went On A Buying Spree
Via Talk Markets
7 Dividend Aristocrats That Will Pay You for Years to Come
Via InvestorPlace
CERE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Cerevel Therapeutics Holdings, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
Via Benzinga
Is AbbVie Stock a Buy Now?
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc. (Nasdaq - ICVX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc.
From Brodsky & Smith LLC
Via GlobeNewswire
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.